- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01532518
Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance
A Multicenter, Open Label, Ascending 7 Day-Repeated Dose Study to Investigate Efficacy, Safety and Pharmacokinetics of Nepadutant In Infants With Feeding Intolerance
Study Overview
Detailed Description
Feeding intolerance is a transient neuro-developmental phenomenon affecting 25% to 40% of infant and toddler, with a peak at 6 weeks of age. Feeding problems include mainly vomiting, slow feeding, refusal to eat and colic.
Current non pharmacological interventions (e.g. message, restriction in maternal diet in breast-feeding infants) and pharmacological treatments (simethicone, antimuscarinic drugs and antiacids) are largely unsatisfactory.
Nepadutant is postulated to have a therapeutic effect in infant colic since it reverts exaggerated intestinal motility and sensitivity induced by different stimuli through the activation of neurokinin-2 receptors, without interferring on the on physiological gastrointestinal transit.
This phase IIa study is designed to test in each participant infant two out of three oral doses of nepadutant in order to measure its blood levels, safety and efficacy with each dose level to be given for 7 concecutive days.
The experimental clinical phase encompasses the following periods:
- Screening period (no study medication), lasting approximately 7 days prior to randomization
- Treatment period, lasting fourteen days (7 days fore each dose)with once daily administration
- A safety follow-up visit, approximately four weeks after start of treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Arkansas Children's Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Children's Center for Digestive Healthcare
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Kosair Charities Pediatric Clinical Research Unit / University of Louisville
-
-
New York
-
Albany, New York, United States, 12207
- SUNY Downstate Medical Center
-
-
Ohio
-
Toledo, Ohio, United States, 43606
- The University of Toledo College of Medicine\The Toledo Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Infants with a clinical diagnosis of feeding intolerance.
- Age ≤ 6 months at the enrolment.
- Normal growth.
- Infants who can refrain from use of erythromycin, metoclopramide, antihistaminic drug, proton pump inhibitors (PPIs), antacids, antimuscarinic drugs, simethicone and dimethicone from 1 week prior randomization until end of study.
Exclusion Criteria:
- Any clinically relevant event (excluding those relevant to the condition under study) which has occurred within one week prior to randomization.
- Any pharmacological treatment starting within one week prior to randomization.
- Infants for whom a change in the diet (i.e. weaning) has been performed within one week prior to randomization or is planned during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 3
Nepadutant low dose (0.1mg/kg) for 7 days followed by Nepadutant high dose (1mg/kg) for additional 7 days
|
Nepadutant oral solution
Other Names:
|
Experimental: Cohort 2
Nepadutant medium dose (0.5mg/kg) for 7 days followed by Nepadutant high dose (1mg/kg) for additional 7 days
|
Nepadutant oral solution
Other Names:
|
Experimental: Cohort 1
Nepadutant low dose (0.1mg/kg) for 7 days followed by Nepadutant medium dose (0.5mg/kg) for additional 7 days
|
Nepadutant oral solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Absolute Differences of I-GERQ-R Total Score at V3 (End of First Week of Treatment) Respect to the Baseline (V2).
Time Frame: Baseline (V2) and end of first week of treatment (V3)
|
Results obtained at V2 serve as baseline values for the assessment of effects at V3 (i.e. end of first week of treatment). Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R ), with a minimum-maximum score of 0-42 (minimum for diagnosis >15). The higher values reflect worse outcome. The questionnaire comprised 12 items as questions quantifying aspects of regurgitation (3 questions), crying (3 questions), feeding refusal (2 questions), apnea/cyanosis (2 questions), hiccups and arching. Questions with 4 possible options have a score ranging from 0 to 3; questions with 5 possible options have a score ranging from 0 to 4. The scores of each item are summed, so the total score is presented. |
Baseline (V2) and end of first week of treatment (V3)
|
The Absolute Differences of I-GERQ-R Total Score at V4 (End of 2nd Week of Treatment) Respect to V3 (End of 1st Week of Treatment).
Time Frame: V3 (end of 1st week of treatment) and V4 (end of 2nd week of treatment)
|
The results obtained at V3 are used as baseline for the second week treatment period (V4). Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R ), with a minimum-maximum score of 0-42 (minimum for diagnosis >15). The higher values reflect worse outcome. The questionnaire comprised 12 items as questions quantifying aspects of regurgitation (3 questions), crying (3 questions), feeding refusal (2 questions), apnea/cyanosis (2 questions), hiccups and arching. Questions with 4 possible options have a score ranging from 0 to 3; questions with 5 possible options have a score ranging from 0 to 4. The scores of each item are summed, so the total score is presented. |
V3 (end of 1st week of treatment) and V4 (end of 2nd week of treatment)
|
The Absolute Differences of I-GERQ-R Total Score at V5 (Follow-up) Respect to V2 (Baseline).
Time Frame: Baseline (V2) and follow up 2 weeks after the last administered dose (V5)
|
Results obtained at V2 serve as baseline values for follow-up assessment 2 weeks after the last administered dose (V5) Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R ), with a minimum-maximum score of 0-42 (minimum for diagnosis >15). The higher values reflect worse outcome. The questionnaire comprised 12 items as questions quantifying aspects of regurgitation (3 questions), crying (3 questions), feeding refusal (2 questions), apnea/cyanosis (2 questions), hiccups and arching. Questions with 4 possible options have a score ranging from 0 to 3; questions with 5 possible options have a score ranging from 0 to 4. The scores of each item are summed, so the total score is presented. |
Baseline (V2) and follow up 2 weeks after the last administered dose (V5)
|
I-GERQ-R Score Changes vs Baseline (Visit 2) by First Dose Level (0.1mg/kg and 0.5mg/kg).
Time Frame: Baseline (V2) and end of 1st week of treatment(V3)
|
Change in Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) Score. Assessing the I-GERQ-R score changes vs baseline (Visit 2) by first dose level (0.1mg/kg and 0.5mg/kg). Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R ), with a minimum-maximum score of 0-42 (minimum for diagnosis >15). The higher values reflect worse outcome. The questionnaire comprised 12 items as questions quantifying aspects of regurgitation (3 questions), crying (3 questions), feeding refusal (2 questions), apnea/cyanosis (2 questions), hiccups and arching. Questions with 4 possible options have a score ranging from 0 to 3; questions with 5 possible options have a score ranging from 0 to 4. The scores of each item are summed, so the total score is presented. |
Baseline (V2) and end of 1st week of treatment(V3)
|
I-GERQ-R Score Changes vs Visit 3 by Second Dose Level (0.5mg/kg and 1mg/kg).
Time Frame: end of first week of treatment (V3) and end of second week of treatment (V4)
|
Change in Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) Score. Assessing the I-GERQ-R score changes vs Visit 3 by second dose level (0.5mg/kg and 1mg/kg). Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R ), with a minimum-maximum score of 0-42 (minimum for diagnosis >15). The higher values reflect worse outcome. The questionnaire comprised 12 items as questions quantifying aspects of regurgitation (3 questions), crying (3 questions), feeding refusal (2 questions), apnea/cyanosis (2 questions), hiccups and arching. Questions with 4 possible options have a score ranging from 0 to 3; questions with 5 possible options have a score ranging from 0 to 4. The scores of each item are summed, so the total score is presented. |
end of first week of treatment (V3) and end of second week of treatment (V4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and Severity of AEs_ Number of Adverse Events by Treatment Dose Level
Time Frame: up to 4 weeks
|
The analysis is by treatment - Each infant was treated with two out of three ascending dose (0.1, 0.5 or 1.0 mg/kg), therefore counted in more than one dose level.
|
up to 4 weeks
|
A Population Pharmacokinetic Analysis to Characterize the Plasma Concentration-time Course for Nepadutant in Infant With Colics From NIC-04
Time Frame: 0.5, 1, 2, 3 hours post Single Dose and 24 hours post Repeated Dose
|
The population pharmacokinetic analyses is presented.
PopPK Clearance estimated with a one compartment model with first order absorption and elimination.
|
0.5, 1, 2, 3 hours post Single Dose and 24 hours post Repeated Dose
|
A Population Pharmacokinetic Analysis to Characterize the Plasma Concentration-time Course for Nepadutant in Infant With Colics From NIC-04
Time Frame: 0.5, 1, 2, 3 hours post Single Dose and 24 hours post Repeated Dose
|
PopPK Volume estimated with a one compartment model with first order absorption and elimination.
NOTE: for this measure, no inter-individual variability was estimated, therefore the value for each cohort corresponds to the typical value.
|
0.5, 1, 2, 3 hours post Single Dose and 24 hours post Repeated Dose
|
A Population Pharmacokinetic Analysis to Characterize the Plasma Concentration-time Course for Nepadutant in Infant With Colics From NIC-04
Time Frame: 0.5, 1, 2, 3 hours post Single Dose and 24 hours post Repeated Dose
|
The population pharmacokinetic analyses is presented.
PopPK Ka estimated with a one compartment model with first order absorption and elimination.
NOTE: for this measure, no inter-individual variability was estimated, therefore the value for each cohort corresponds to the typical value.
|
0.5, 1, 2, 3 hours post Single Dose and 24 hours post Repeated Dose
|
A Population Pharmacokinetic Analysis to Characterize the Plasma Concentration-time Course for Nepadutant in Infant With Colics From NIC-04
Time Frame: 0.5, 1, 2, 3 hours post Single Dose and 24 hours post Repeated Dose
|
The population pharmacokinetic analyses is presented.
The PopPK parameter fraction of the dose absorbed (F1) is estimated with a one compartment model with first order absorption and elimination.The results are presented fraction of the absorbed dose with 95% CI of the parameter estimate value
|
0.5, 1, 2, 3 hours post Single Dose and 24 hours post Repeated Dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIC-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colic
-
SOFAR S.p.A.CompletedInfantile Colic | Colic, InfantileItaly
-
University of NebraskaiHealthTerminatedInfantile ColicUnited States
-
Lallemand Health SolutionsProbiSearch SLWithdrawn
-
BioGaia ABHopital Universitaire Robert-Debre; Association Clinique Thérapeutique Infantile... and other collaboratorsWithdrawnInfantile ColicFrance
-
Nordic Institute of Chiropractic and Clinical BiomechanicsResearch Unit of General Practice, OdenseCompleted
-
Innovacion y Desarrollo de Estrategias en SaludBioGaia ABUnknown
-
University of SevilleCompleted
-
University of BariAntonio Di Mauro; Ruggiero Francavilla; Lorenzo TrovèUnknown
-
Nordic Institute of Chiropractic and Clinical BiomechanicsUniversity of Southern Denmark; Foundation for the Advancement of Chiropractic...TerminatedInfantile ColicDenmark
-
Menarini GroupWithdrawn
Clinical Trials on Nepadutant
-
Menarini GroupWithdrawn
-
Menarini GroupCompletedInfantile ColicRussian Federation, Germany, Poland, Sweden
-
Menarini GroupCompletedInfantile Colic | Infantile Functional Gastrointestinal DisordersUnited States